TATVA share price, P/E, ROE & financials

Tatva Chintan Pharma Chem (TATVA) had a P/E of 59.7× on 6 Nov 2026, above the industry P/E of 22.1×, and the shares are 24% below their 52-week high. Its ROCE of 7.5% is the lowest among the 7 largest Specialty Chemicals peers, and sales grew 6.0% a year over 3 years while net profit fell 2.6%. Its dividend yield is 0.1%, and debt is 0.21× equity. It is a small-cap company with a market cap of ₹3,756 Cr, ranked 41st of 204 Specialty Chemicals companies by market cap; the shares rose 9.0% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹1,650.00
Day high: ₹1,663.00
Day low: ₹1,585.00
Prev. close: ₹1,665.60
Volume: 55.4K

Health check

1 good · 2 fair · 3 to check

ReturnsIn line
+9.0% over a year, better than 4 of 7 peers.
Price tagPricier
P/E 59.7 vs industry 22.1.
GrowthSteady
Sales +6.0%, profit −2.6% a year over 3 years.
ProfitabilityWeak
ROCE 7.5% vs peer median 24.4%.
Balance sheetSolid
Debt 0.21× equity, interest covered 22.8×, Piotroski 7 of 9.
Red flags1 to check
P/E of 59.7 against an industry P/E of 22.1.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Specialty Chemicals

203 listed peers. Screen the industry

Small cap

₹3,756 Cr, #41 of 204 in its industry by size.

Defensive

Beta 0.32 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹650 Cr · profit ₹63 Cr

Market cap: ₹3,756 Cr; Small cap
P/E: 59.7; Industry 22.1
Price to book: 4.61; Peers 13.33
Dividend yield: 0.12%
ROE: 8.0%; Peers 23.0%
ROCE: 7.5%; Peers 24.4%
Debt to equity: 0.21; Debt ₹170 Cr
EPS (TTM): ₹26.90; Face value ₹10
OPM (TTM): 19.5%; Net margin 9.7%
Sales growth: +75.9%; Latest quarter vs a year ago
Profit growth: +116.3%; Latest quarter vs a year ago
Price to sales: 5.78; EV/EBITDA 30.6

Strengths

Quarterly profit up 116.3% on a year ago.
Quarterly sales up 75.9% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

P/E of 59.7 against an industry P/E of 22.1.

Derived automatically from reported figures. Not a recommendation.

About Tatva Chintan Pharma Chem

Tatva Chintan Pharma Chem Limited engages in the manufacture and sale of specialty chemicals in India, Germany, the United States of America, China, Singapore, and internationally. It offers structure directing agents (SDAs); phase transfer catalysts (PTCs); electrolyte salts for super capacitor batteries; pharmaceutical and agrochemical intermediates, and other specialty chemicals (PASC); and brominated flame retardants. The company serves automotive,…

Headquarters: Vadodara
Employees: 793
Sector: Basic Materials
ISIN: INE0GK401011
Website: tatvachintan.com

Price range

52 weeks

₹1,044.10₹2,113.60

Today

₹1,585.00₹1,663.00

Avg volume (3M): 92.4K
1-year return: plus 9.0%
From 52-week high: minus 24.0%

Peers · Specialty Chemicals

Capital-heavy industry columns

Compare with peers Screen the whole industry

Company
ASIANPAINTAsian Paints	2,546.00	plus 0.88%	2,44,025	50.5	35.0	24.4%	18.9%	0.21	1.1%	plus 1.5%
SOLARINDSSolar Industries India	18,608.00	plus 0.48%	1,68,384	74.4	64.1	29.5%	27.8%	0.22	12.4%	plus 35.9%
PIDILITINDPidilite Industries	1,579.00	plus 1.63%	1,60,827	60.0	44.4	28.5%	23.5%	0.03	7.4%	plus 6.8%
LINDEINDIALinde India	6,859.00	plus 8.73%	58,496	118.4	64.2	16.3%	31.5%	0.23	–	plus 5.4%
BERGEPAINTBerger Paints India	478.35	minus 5.28%	55,776	45.4	29.4	20.6%	15.3%	0.15	4.2%	minus 6.0%
FLUOROCHEMGujarat Fluorochemicals	4,665.50	minus 0.94%	51,251	75.9	44.0	9.6%	24.1%	0.26	−4.5%	plus 28.0%
ACUTAASAcutaas Chemicals	3,786.60	plus 0.42%	31,001	70.9	64.1	27.7%	39.4%	0.01	29.4%	plus 105.6%
TATVATatva Chintan Pharma Chem	1,605.80	minus 3.59%	3,756	59.7	40.2	7.5%	13.8%	0.21	6.0%	plus 9.0%
Median of 7 peers	–	0.48%	58,496	70.9	44.4	24.4%	24.1%	0.21	5.8%	6.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
124	131	134	167	217
101	106	106	135	177
22.2	25.5	28.1	32.3	40.7
18.0%	19.4%	21.0%	19.3%	18.7%
1	1.7	−0.3	2.8	1.8
0.5	0.5	1.4	2.1	2.7
9.1	9.1	9.8	10.6	10.8
–	–	–	−1.3	–
13.7	17.7	16.6	21.1	28.9
27.4%	14.1%	37.8%	24.3%	25.9%
9.9	15.2	10.3	16	21.5
4.24	6.49	4.41	6.83	9.17

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +6.0%
Profit CAGR 3Y: −2.6%
EPS CAGR 3Y: −4.3%
ROE: 8.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
421	390	380	501
–	minus 7.2%	minus 2.7%	+31.8%
353	321	345	404
68.3	69.7	34.6	96.3
16.2%	17.9%	9.1%	19.2%
−2.2	5.7	1.6	0.3
8	6.2	0.9	2.6
9.6	25.6	27.7	36.8
−3.8	−0.1	−0	−0.1
44.8	43.6	7.6	57
−1.6%	30.3%	24.6%	26.2%
45.5	30.4	5.7	42.1
–	minus 33.3%	minus 81.2%	+636.1%
20.52	13.26	2.44	17.98

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
22.2	23.4	23.4	23.4
493	714	715	758
170	14.3	36.4	120
73.8	67.4	61	102
759	819	836	1,004
427	499	547	627
231	72.9	21.5	23.3
2.8	–	0	4.4
41.2	45.7	11.7	6.1
57.5	201	256	342
759	819	836	1,004

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
27.8	98	24.8	31.5
−101	−121	−65.4	−116
37.8	30.5	16.6	78.9
−35.6	8	−24	−5.4
−203	−129	−76.3	−114
−175	−30.5	−51.5	−82.3
−4.4	−4.7	−4.7	−2.3

Shareholding pattern

Source: NSE filings

72.0%

promoters

Promoters72.02%
Public27.98%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	72.02%	27.98%	0.00
30 Jun 2026	72.02%	27.98%	0.00
31 Mar 2026	72.02%	27.98%	0.00
31 Dec 2025	72.02%	27.98%	0.00
30 Sep 2025	72.02%	27.98%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you